Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
16,210
+440 (2.79%)
Nov 20, 2025, 3:30 PM KST

Onconic Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21
700,930176,537---
Enterprise Value
647,516152,373---
Last Close Price
15770.004085.00---
PS Ratio
15.0211.90---
PB Ratio
10.183.15---
P/TBV Ratio
10.183.15---
EV/Sales Ratio
13.8810.27---
Debt / Equity Ratio
0.000.01-0.060.00-0.02
Debt / EBITDA Ratio
0.01-0.13--
Debt / FCF Ratio
0.02-0.12--
Asset Turnover
0.870.300.620.00-
Quick Ratio
12.6410.610.711.0636.08
Current Ratio
13.2110.940.711.0636.10
Return on Equity (ROE)
33.75%-32.29%---
Return on Assets (ROA)
14.36%-6.09%4.07%-36.85%-
Return on Capital (ROIC)
15.50%-11.81%---
Return on Capital Employed (ROCE)
18.00%-8.50%-39.40%-343.70%-44.10%
Earnings Yield
2.39%-4.58%---
FCF Yield
1.01%-4.52%---
Buyback Yield / Dilution
--1314.60%90.00%-0.94%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.